Augmenting the Benefit of Hormonal Therapy in Breast Cancer

Clinical Pearls

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses augmenting the benefit of hormonal therapy in breast cancer.

• The CDK4/6 inhibitor palbociclib has yielded exciting preliminarily results
• In a phase II study, the combination of palbociclib and letrozole tripled PFS compared with letrozole alone (26.1 months versus 7.5 months)
• The HDAC inhibitor entinostat plus hormonal therapy was found to improve survival in a phase II study
• Src inhibition showed benefit in a trial